Observational studyJournal of neuro-oncology2026
Upfront stereotactic radiosurgery for large posterior fossa metastases: a multicenter evaluation of clinical outcomes.
Observational study in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeManagement of large posterior fossa metastases is challenging due to proximity to critical neuroanatomical structures and the potential need for urgent surgical decompression. While surgical resection is traditionally favored for large or symptomatic lesions, the role of upfront stereotactic radiosurgery (SRS) remains incompletely defined. This study aims to evaluate the clinical, radiological, and survival outcomes of upfront SRS for large cerebellar metastases to assess its viability as a primary treatment.
methodsThis retrospective, two-institution study (2007–2024) included 61 adults with large cerebellar metastases (volume ≥ 5 cm³). Primary outcomes were overall survival (OS), local control (LC), and subsequent neurosurgical intervention. Secondary outcomes included tumor volume reduction.
resultsMean tumor volume was 11.9 cm³. LC was achieved in 93% of evaluable patients. Median OS was 12.6 months, with estimated survival rates of 68%, 54%, and 43% at 6, 12, and 24 months, respectively. Significant tumor mass reduction occurred following SRS (mean decrease 6.16 cm³, p < 0.001). Only 5% of patients required post-treatment neurosurgery. On multivariable analysis, a greater number of treatment fractions was associated with improved survival, whereas higher total radiation dose was associated with worse survival.
conclusionsUpfront SRS for large posterior fossa metastases provides excellent LC, significant volume reduction, and favorable survival, while rarely necessitating subsequent surgical intervention. These findings suggest that, in carefully selected patients, SRS may serve as an effective primary treatment strategy that can obviate the need for surgical resection, even in large-volume posterior fossa disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.